Sartorius (OTCMKTS:SARTF) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Sartorius (OTCMKTS:SARTF) from a buy rating to a hold rating in a report published on Thursday morning, reports.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Separately, DZ Bank reissued a sell rating on shares of Sartorius in a report on Friday, July 19th.

Shares of OTCMKTS:SARTF opened at $164.10 on Thursday. The firm has a fifty day moving average price of $181.39 and a two-hundred day moving average price of $169.04. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.53 and a quick ratio of 0.85. Sartorius has a one year low of $109.50 and a one year high of $192.10. The company has a market cap of $5.61 billion, a price-to-earnings ratio of 54.34 and a beta of -0.06.

Sartorius (OTCMKTS:SARTF) last announced its quarterly earnings results on Friday, July 19th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.07. Sartorius had a net margin of 11.10% and a return on equity of 20.23%. The firm had revenue of $515.83 million during the quarter, compared to the consensus estimate of $482.51 million. Equities research analysts expect that Sartorius will post 3.53 EPS for the current fiscal year.

About Sartorius

There is no company description available for Sartorius AG.

See Also: What is the return on assets (ROA) ratio?

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with's FREE daily email newsletter.